238 related articles for article (PubMed ID: 21725052)
1. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P; Barosi G; Rambaldi A; Marchioli R; Masciulli A; Tozzi L; Biamonte F; Bartalucci N; Gattoni E; Lupo ML; Finazzi G; Pancrazzi A; Antonioli E; Susini MC; Pieri L; Malevolti E; Usala E; Occhini U; Grossi A; Caglio S; Paratore S; Bosi A; Barbui T; Vannucchi AM;
Blood; 2011 Aug; 118(8):2069-76. PubMed ID: 21725052
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
4. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.
Du X; Zhou D
Front Med; 2016 Dec; 10(4):437-443. PubMed ID: 27858230
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
13. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
16. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Witzig TE; Reeder CB; LaPlant BR; Gupta M; Johnston PB; Micallef IN; Porrata LF; Ansell SM; Colgan JP; Jacobsen ED; Ghobrial IM; Habermann TM
Leukemia; 2011 Feb; 25(2):341-7. PubMed ID: 21135857
[TBL] [Abstract][Full Text] [Related]
18. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Gisslinger H; Schalling M; Gisslinger B; Skrabs C; Müllauer L; Kralovics R
Am J Hematol; 2014 Mar; 89(3):344-6. PubMed ID: 24273107
[No Abstract] [Full Text] [Related]
19. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
20. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
